News
Clinical Trials Arena on MSN12d
AstraZeneca’s Truqap fails in another Phase III trialThe CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen-deprivation therapy ...
The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...
India Today on MSN4d
India expands use of AstraZeneca's drug for advanced breast cancer casesThe medicine, Trastuzumab deruxtecan, was already available for some breast and stomach cancers. It has been approved to ...
A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...
AstraZeneca ... cancer charities. The medicine has been found to double the life expectancy for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The ...
AstraZeneca has ... was investigating the drug in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback